FDA Approves Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder DUBLIN, June 1, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Lybalvi (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with… Read More »
May 1, 2021 Approval is based on demonstrated reduction in liver iron concentration Expanded indications for patients with sickle cell disease or other anemias, as well as thalassemia – BOSTON, May 1, 2021 /PRNewswire/ — Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today… Read More »
Since hair quality is a potent vitality signal, and hair growth deficiency can cause significant psychological impact to many, finding alternative and natural treatments to help combat hair loss is a thriving business. In addition to clearly defined hair loss disorders, milder forms of hair thinning, or hair loss appear to be increasingly common, with… Read More »
A US study has concluded that weight gain is greater by around 2 to 4 kg in HIV-positive people taking bictegravir or dolutegravir as part of their first antiretroviral therapy (ART), compared to their counterparts using other drug regimens. A similar effect was reported in those using the protease inhibitor darunavir. The study led by… Read More »